Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Eligible age
12–18 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM. .
Sponsor: University of Alberta
You may qualify if…
- ✓ 1. Age 12-18 years
- ✓ 2. BMI percentile \> 95% for age/sex;
- ✓ 3. Total weight fluctuation over past 6 months \< 10%;
- ✓ 4. HOMA-IR \> 3.16;
- ✓ 5. FH of T2DM (first or second-degree relative).
You may not qualify if…
- ✕ 1. Current use of insulin or diagnosis of T2DM;
- ✕ 2. Systolic or diastolic blood pressure (BP) \> 99th percentile for age and sex;
- ✕ 3. Acute infectious or inflammatory condition over the preceding 1 month; hospitalization \> 48 hrs;
- ✕ 4. History of chronic disease such as inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders;
- ✕ 5. Active malignancy;
- ✕ 6. Concomitant use of medication/investigational drug known to affect body weight in the past year;
- ✕ 7. Antibiotic use in past 60 days; probiotic and/or prebiotic supplements use in the past 30 days; use of lipid-lowering and anti-inflammatory medication.
Source: ClinicalTrials.gov · NCT04578652 · last updated 2025-11-17